Antenna Group Expands Global Footprint with Acquisition of Czech Republic’s Rubikon PR
4.9.2024 13:00:00 EEST | Business Wire | Press release
Antenna Group announced today the acquisition of Rubikon PR, a leading Czech public relations and marketing firm. This move marks a significant expansion of Antenna Group's European operations and reinforces its commitment to driving positive global change through innovative communication strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240904319818/en/
(Graphic: Business Wire)
Founded in 2012, Rubikon is known for its expertise in social impact, fintech, real estate, technology, and the industrial sector. By seamlessly integrating Rubikon into its global operations, Antenna is both expanding its global footprint and enhancing its ability to deliver creative, data-driven solutions at scale. This strategic integration will provide Rubikon's impressive client roster - including Too Good To Go, Freedom Finance, and SkyShowtime - with access to Antenna Group’s full-stack digital marketing, communications, and public affairs services, as well as its deep domain expertise, and award-winning creative talent.
The synergy created by this union is particularly timely given the Czech Republic's burgeoning climate tech sector. Consumer-friendly regulations in the Czech Republic have made it easier for homeowners to install rooftop solar, and the utility-scale solar industry is in its early stages of development. With a 236% increase in installed PV capacity in 2023, the Central and Eastern European (CEE) region and the European Union present exciting opportunities for sustainable growth and innovation.
"We are thrilled to welcome Rubikon into the Antenna Group family,” said Keith Zakheim, CEO of Antenna Group, “The acquisition is a significant milestone for Antenna as it further strengthens our ability to partner with global companies that are fostering innovation, driving sustainable growth across the planet and making a meaningful impact at scale. This union is not just an expansion of our geographical footprint; but, it amplifies our ability to craft impactful narratives that resonate across borders. This partnership embodies our commitment to fostering a more sustainable future through the power of storytelling, creativity, and technology. Together, we're poised to break new ground, connecting brands with audiences across borders and driving positive change in an increasingly interconnected world."
Šimon Rákosník, EVP of CEE Region, added, "Joining Antenna Group opens up a world of possibilities for our clients and our team. We're excited to combine our local insights with Antenna’s global expertise, particularly in areas like cleantech and sustainable technologies. Together, we're poised to create communication strategies that drive business success and contribute to solving some of the world's most pressing challenges."
This acquisition, following its recent expansion into London, underscores Antenna Group’s dedication to building a truly global, integrated network that can meet clients' evolving needs in an increasingly complex marketplace. By combining Rubikon's regional expertise with its worldwide resources, Antenna is building a powerhouse capable of delivering unparalleled value and driving positive change across North America, Europe, and beyond.
ABOUT ANTENNA GROUP
Antenna Group is a global integrated marketing and communications agency partnering with the world’s most exciting and disruptive companies across climate, energy, mobility, real estate, healthcare, and emerging B2B tech sectors. Our clients are transformational and distinguished corporations, startups, investors, and nonprofits at the bleeding edge of the Age of Adoption — the world today in which companies representing every economic sector are furiously adopting climate tech and sustainable solutions. To learn more, please visit antennagroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904319818/en/
Contacts
Media:
Isaac Steinmetz
Antenna Group
isaac.steinmetz@antennagroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom